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This edition of Advance
highlights the fact
that the University of
Tennessee Medical
Center and UT Graduate
School of Medicine are
involved in collaborative
research with other
institutions. Our
research enterprise has
grown so vast that partnering with different
organizations often is the most robust way to
focus diverse expertise on a single problem.
Our institutions collaborate with the
University of Tennessee, Knoxville, College
of Engineering, School of Public Health,
Department of Nutrition and College of
Veterinary Medicine, as well as Oak Ridge
National Laboratory (ORNL) and the UT
Health Science Center in Memphis to name
a few. The valuable partnerships formed by
these joint efforts lead to better research. These
partnerships also yield an advantage in obtaining
funding from national organizations.
Many human medical problems can be solved
through engineering solutions or have analogies
in the veterinary world, where solutions benefit
both human and non-human patients. The
juxtaposition of clinicians and basic scientists
in diverse fields often creates a relationship that
advances research in problems found in clinical
care. Having the computational and nuclear
expertise of ORNL close by enables sophisticated
approaches to complex medical issues.
The Graduate School of Medicine is uniquely
poised to take advantage of these resources, and
as part of an academic medical center, we are
using collaborative opportunities to advance our
knowledge, understanding and treatment of the
ailments of our patients.
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The Curiosity of
»»»»»»

Amy LeBlanc and husband, Casey, enjoy reading with
their daughters, Erica and Isabelle. LeBlanc’s research that
combines animal and human health is unique in the world.

“I think my parents would say I was academic
to begin with, and I loved animals and science
from a young age,” says LeBlanc with a quick
laugh that fills the room.
For most of her life, LeBlanc thought she
would become a veterinarian in a private practice.
Eventually, her sense of curiosity told her otherwise.
During her veterinary school years, LeBlanc
became fascinated with oncology and decided
she wanted to delve into that specialty by
pursuing additional post-graduate training. After
completing a medical oncology residency, LeBlanc
began practicing veterinary oncology in Tampa,
Florida. While she enjoyed the work, she had “a
nagging feeling that this can’t be all there is,” she
says. “I realized I wanted to be on the edge of
what’s known and what’s not known.”

Some people have it. Some simply do not. It’s
a deep sense of curiosity. It’s asking, “Why” and
“What if” and not being satisfied until an answer
is found.
Thankfully, Amy LeBlanc, D.V.M., associate
professor and director of Translational Research,
Molecular Imaging and Translational Research
Program, possesses that deep curiosity and the
education and skills to act upon it to the benefit of
patients. But the unique part of LeBlanc’s story is
that for her, patients are both the two-legged and
four-legged varieties.
In a unique joint position with the UT
Graduate School of Medicine and the UT College
of Veterinary Medicine, LeBlanc studies noninvasive ways to detect and monitor response to
treatment for diseases in dogs, and in front of
her is an ever-widening field of opportunities to
translate her findings to the detection and care of
diseases in humans.

We need to know what
before we can understa
A Curious Turn of Events
In May 2004, she and husband, Casey, a
veterinary clinical pathologist, moved to Knoxville
to accept faculty positions at the UT College of
Veterinary Medicine.
“Almost never are two positions like those

Academic to Begin With
LeBlanc’s father is a chemical engineer, and her
mother is a teacher.
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Amy LeBlanc
open at the same time,” LeBlanc says in
amazement. “It just never happens. But
we are lucky to be here in Knoxville.”
In line with a typical tenure-track
faculty position at the Veterinary Medical
Center, LeBlanc was able to begin research
while fulfilling clinical service and
teaching roles. She soon learned about
incredible technology available just across
the Tennessee River at the UT Graduate
School of Medicine, and by 2009, with
the encouragement of James Neutens,
Ph.D., dean of the Graduate School of
Medicine, and James Thompson, D.V.M.,
Ph.D., dean of the College of Veterinary
Medicine, LeBlanc had a joint appointment
between the two institutions, doing what she
loves: Answering “what if.”
“It was a natural progression to where I wanted to
focus my research efforts,” LeBlanc says. “We have a
unique set of resources, technology and people that
you cannot find anywhere else in the world.”

One of Amy LeBlanc’s current research programs is
inflammatory brain disease in dogs and how to draw
correlation to human health.

ethically sound and mutually beneficial for
veterinary medicine and human medicine.
Protocols are followed and regularly scrutinized.
At present, LeBlanc is using the non-invasive
PET/CT imaging facility to determine how
normal dog brains use glucose for fuel, so she and
others around the world can compare with brain
activity of dogs suspected of having inflammatory
brain disease.
“We need to know what normal looks like
before we can understand abnormal,” she says.
This study is one of several headed by LeBlanc
that is unique in the world. Nowhere else and
no one else in the world has ever done such
studies. She recounts a time recently when she
attended an international conference and watched
as her research findings were used to support the
presenter’s findings.
“It was an exciting moment, knowing
the work we are doing here is impacting the
way physicians think about diagnosing and
treating their patients,” says LeBlanc. “In the
end, I’d like to see drugs and imaging tools
come into the marketplace for humans and
animals, understanding the knowledge we gain
is transferrable to both. Someone’s mother or
brother will get that drug, which would not
be available if we hadn’t been here, if we hadn’t
wondered about the possibilities.”

Understanding Abnormal

t normal looks like
and abnormal.
~Amy LeBlanc
LeBlanc is putting this unique environment
to good use. Her goal is to help researchers in
various fields realize the potential of PET/CT
(Positron Emission Tomography/Computed
Tomography) imaging. She sees a big picture not
many medical or veterinary professionals see or
know exists: Knowledge gained from using PET/
CT imaging for human health can help animals;
conversely, using PET/CT and new PET tracers
to diagnose and monitor treatment in animals can
further human health.
“Animals with spontaneous diseases, like
heart failure, diabetes and cancer, can help us
understand similar diseases in humans. We have
incredible technology and expertise here, so
we should be asking, ‘How else can we use this
technology to benefit both?’.”
LeBlanc has high demands for her research:
In addition to complying with all regulations
governing research, it must be both
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Healthier Moms
Research is Moving Dreams to Reality

You might call the folks in the
Department of Obstetrics/
Gynecology determined
dreamers.
They are Bobby Howard,
M.D., chair of the department;
Jo Kendrick, W.H.N.P.-B.C.,
certified diabetes educator; and
Dawn Coe, Ph.D., University
of Tennessee, Knoxville,
Department of Kinesiology,
Recreation and Sport Studies.
Through two research
programs, this group is tackling
gestational diabetes and obesity,
two health issues that threaten
the lives and health of pregnant
women and their babies.
If only everyone dreamed as
these professionals do.
In 2009, Kendrick and
Coe teamed to determine the
effect of moderate activity on
controlling gestational diabetes.
Maintaining blood glucose
in pregnant women means
healthier moms and babies.
“My dream is to determine how many steps
it takes each day to maintain normal blood
glucose levels in women with gestational diabetes
to avoid the use of insulin during pregnancy,”
Kendrick says.

First, Kendrick and Coe validated a pedometer
that could be used to accurately count the daily
steps of pregnant women. Then, eight pregnant
women who had gestational diabetes enrolled in
the research study, and throughout the first

Why this matters:

In Tennessee, gestational diabetes affects up to 14%
of pregnancies, and more than one of every three
women in East Tennessee is obese. Research that
brings healthier babies into the world, who go home
with healthier mothers, affects generations.
4

and Babies:
part of 2011, each woman had her blood glucose
continuously monitored during moderateintensity walking and sedentary trials.
“The results were significant,” Coe says.
“We learned that moderate activity only
one time each day sustained lower blood
glucose levels for up to three hours.”
Now, the next phase—a larger
cohort who will undergo different levels
of prescribed activity and monitoring—
will continue through 2013.
Obesity is another health threat
to women and babies’ health during
pregnancy, one that Bobby Howard,
M.D., dreams of eradicating.
“We know that during
pregnancy, obesity results in
complications including a higher rate of
Cesarean delivery, surgical complications,
anesthesia complications and impaired

wound healing,” Howard says. “The baby’s
health also is compromised with an increased risk
of birth defects, macrosomia and stillbirth.”
Howard has embarked on a research program
that will help educate pregnant women about the
risks of obesity to their and their babies’ health as
well as help them monitor their diet and activity
levels. Using today’s technology helps.
Each woman in the study has been provided
pedometers and an internet-capable device for
documenting their daily activity and food intake
on a specially designed web site. Howard and
others will access the information to help their
patients understand how to adjust their lifestyles
to combat obesity—and have healthier babies.

Dawn Coe, Ph.D., Bobby Howard, M.D., and Jo Kendrick,
W.H.N.P.-B.C., are tackling gestational diabetes and obesity
to help ensure healthy moms and babies.
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An Urgent Need:
See Plaque in the Brain

Using p5 peptide developed by Jonathan Wall, Ph.D., amyloid in a mouse model glows brightly in a PET scan. The peptide can
breach the blood-brain barrier and is helping researchers determine the cause of Alzheimer’s and other diseases.

Jonathan Wall, Ph.D., a professor and director
of Preclinical and Diagnostic Molecular Imaging
Laboratory and his collaborators, Steven Kennel,
Ph.D., and Amy
LeBlanc, D.V.M.,
have developed
and are testing new
imaging agents that
might be good for
patients who suffer from amyloid-related diseases
like Alzheimer’s disease and Type 2 diabetes, as
well as certain cancers, such as melanoma.
People with Alzheimer’s and Type 2 diabetes
develop amyloid, a substance comprised of sticky
protein fibers and sugar molecules. Doctors

are uncertain what role amyloid plays in these
diseases, but they believe it causes destruction
of brain cells and the insulin-making cells in the
pancreas. Because of
this uncertainty, there
is an urgent need to
see the sticky substance
to accurately diagnose
and stage disease and
monitor therapies patients are using. Until now,
seeing amyloid in these patients occurred only in
autopsies.
Wall has developed a new peptide imaging
agent, a tiny protein he’s named “p5.” This
peptide seeks out and binds special sugar

Peptide p5 is the only
imaging agent in the
world to bind the sugar
molecules in amyloid or
tumors. It is unique.

Why this matters:

While p5 does not yet destroy amyloid, it does bind
to every type of amyloid. It brings us one giant
leap closer to understanding Alzheimer’s disease
and diabetes and in developing rapid methods
for accurate diagnosis and treatment strategies,
leading ultimately to a cure for amyloid-associated
diseases and cancer.
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Jonathan Wall, Ph.D.

molecules that are found in amyloid deposits and
surprisingly on certain tumor cells, including
melanoma tumors. Under the right conditions,
the p5 peptide can breach the blood-brain barrier
and through PET (positron emission tomography)
scans and other techniques has been shown in
preclinical tests to stick to amyloid in the brains of
animals with Alzheimer’s-like disease.
Wall expects that with appropriate
modifications, p5 may eventually image amyloid
in patients with Alzheimer’s disease and diabetes
better than other imaging agents because it can
specifically seek the amyloid. Peptide p5 is
the only imaging agent in the world to bind
the sugar molecules in amyloid or tumors.
It is unique.
In addition, Wall and Kennel have
been able to detect melanoma tumors on
animals that are brought by their owners for
care. LeBlanc uses this technique to assist in
the diagnosis and monitoring of dogs suffering
with melanoma.

“In the U.S., our ability to detect amyloid
deposits is limited,” said Wall. “We’ve made
amazing progress, but we need to move faster. P5
is the next generation of amyloid imaging agents,
and it holds much promise for helping people
with Alzheimer’s and diabetes as well as those
suffering from certain forms of cancer.”
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Clinical Trials:
Providing Answers
Clinical trials are
medical research
that helps bring new
devices, vaccines or
drugs more quickly to
patients. As part of an
academic medical center
environment, physicians
and researchers at the
Graduate School of
Medicine conduct
clinical trials to pursue
answers for their patients and advance the field of
medicine overall.
Scott Stevens, M.D., is a professor in the
department of Surgery and a passionate researcher
in vascular pathology. He heads the University of
Tennessee Medical Center Aorta Center, the only
site in East Tennessee to be selected to participate in
an FDA-approved clinical trial studying stent repair
of Acute Complicated Type B Aortic Dissections
(Medtronic Dissection Trial—U.S. Study). This
is an investigational device, limited by Federal (or
United States) law to investigational use.
This study represents a joint effort of the
cardiothoracic, vascular and endovascular services
at the Aorta Center to provide available options
to treat patients with this highly challenging and
lethal disease. The trial currently is enrolling.
Stevens also leads several registry programs,
which are post-approval studies of devices in use.
One registry is assessing outcomes of the use of
stents with distal protection in the treatment of
obstructive carotid artery disease. Another is
assessing the use of thrombectomy with varying

catheter lengths for patients with peripheral
vascular disease; embolism and thrombosis; or
venous thrombosis.
For more information about these studies,
contact Susan Rawn, coordinator, Clinical
Research, at 865-305-9227.
Clinical trials at the University of Tennessee
Medical Center also are ongoing. One trial
currently under way investigates the recurrence of
tumors in patients with non-small cell lung cancer.
The trial, called MAGRIT, is sponsored by
GlaxoSmithKline, a pharmaceutical company, and
is being conducted at several centers around the
world. Currently open for enrollment, MAGRIT
evaluates an investigational lung cancer treatment
called MAGE-A3 ASCI (antigen-specific cancer
immunotherapeutic). ASCI works with the
patient’s own immune system to fight the cancer.
In this study, the treatment specifically targets
the MAGE-A3 antigen, which is a substance
sometimes found on lung cancer cells.
The purpose of MAGRIT is to measure how
well the MAGE-A3 ASCI works in preventing
cancer from coming back when given to patients
with non-small cell lung cancer whose tumors
express MAGE-A3 and who have had tumors
removed by surgery.
For more information about the MAGRIT
clinical trial, contact Barbara Munsey, director,
Research Compliance and Oncology Clinical
Trials, at 865-305-7136.

A comprehensive list of clinical trials being
conducted across the country can be found at
www.clinicaltrials.gov.

Why this matters:

Clinical trials provide answers to patients and
physicians and help develop new treatments for a
variety of medical conditions.
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Breakthroughs in Huntington’s
Disease, Type 2 Diabetes
In a major
breakthrough,
Valerie
Berthelier,
Ph.D., assistant
professor and
director of the
Graduate School
of Medcine’s
Conformational
Diseases and
Therapeutics
Laboratory, in
Valerie Berthelier, Ph.D.
collaboration
with Christopher Stanley, Ph.D., Neutron
Scattering Science Division at Oak Ridge
National Laboratory (ORNL), are the first in
the world to image the earliest formation of
the mutant huntingtin protein. This protein
is believed to be responsible for causing
Huntington’s disease, a hereditary neurological
disorder that is always fatal and affects one in
10,000 Americans, and this earliest formation of
the protein is believed to be the most toxic.
Using a neutron-scattering instrument at
ORNL, the team was able to learn how the
protein begins aggregating. Researchers believe
that once the mutant protein forms aggregates,
or clumps, the brain cannot naturally remove
them, leading to Huntington’s disease.
Now that the toxic proteins have been

revealed, the next step is to develop drugs to
combat the formation of clumps or remove the
toxicity of the initial protein. This knowledge
also will aid in the study of other proteinaggregation diseases, including Alzheimer’s and
Parkinson’s.
Berthelier also is investigating the aggregation
of amyloid (dangerous fibrils) in the pancreas,
ultimately to draw a link to Type 2 diabetes.
The pancreas is a gland shaped much like
a bunch of grapes that is located behind the
stomach. It aids in protein digestion and
produces insulin directly into the bloodstream to
help the body metabolize carbohydrates.
When the pancreas cannot produce insulin
or the body does not properly use the insulin
produced, Type 2 diabetes results. But what is
the cause of the pancreas malfunctioning?
Berthelier and her team know patients with
Type 2 diabetes have deposits of amyloid in their
pancreases. While the association of pancreatic
amyloid and development of Type 2 diabetes is
known, a direct causative role for the amyloid has
not been established.
Does the amyloid polypeptide in the pancreas
cause Type 2 diabetes?
The researchers are investigating the
aggregation properties of the amyloid and
identifying small compounds that can alter the
aggregation phenomena.

Why this matters:

Research into the root cause of Huntington’s
disease and Type 2 diabetes can be the first step
in eliminating these diseases that affect millions
of Americans and for people with Huntington’s
disease is always fatal. This research also can
lead to discoveries in other amyloid-associated
diseases, such as Alzheimer’s and Parkinson’s.
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In Brief
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The Growth of Regenerative Medicine
Christopher P. Stephens, Ph.D., is leading
a new research program that is growing…
quite literally.
Regenerative medicine is a field of science
that began in earnest in the 1990s. It combines
medicine and engineering to help the body heal
itself using the body’s own cells to regenerate
organs or tissue. It can be used for skin injuries,
neuromuscular disorders, joint replacements,
cartilage regrowth and organ repair.
In his work, Stephens, a research assistant
professor in the Department of Surgery and
the Center for Materials Processing at the UT
College of Engineering, along with collaborator
Madhu Dhar, Ph.D., at the UT College of
Veterinary Medicine, are developing methods
to induce regeneration using equine stem cells.
Stem cells are not fully differentiated, so they
have the ability to grow into different tissue
types, including bone, muscles and connective
tissue. Stephens’s work requires the use of adult
donated stem cells, not embryonic stem cells,
and horses are used because their physiology is
similar to human conditions and can provide
therapeutic benefit to the companion animal.
In the novel research, stem cells are painlessly
removed from a horse and placed in culture
with a scaffold created by Stephens. With the
ultimate goal of creating scaffolds that encourage
cell growth for various uses, currently Stephens is
conducting initial compatibility testing.
“Our initial scaffold allowed for cell growth

primarily on the
surface,” Stephens
said. “That was
promising, but
the cell growth
needs to infiltrate
the scaffold in
order to produce
a tissue. We are
now developing
Christopher Stephens, Ph.D.,
leads
a growing field of medical
a scaffold that
research: regenerative medicine.
is a naturally
degradable polymer with a pore structure to
enable in-growth of cells. Once we’ve achieved
adequate cell adhesion and growth, that material
will be placed in a horse to promote healing of
the animal’s bone fracture or wound.”
Success means the horse’s body begins
healing itself by regenerating cells using those
implanted—not healing with scar tissue but with
new, healthy tissue.
For Stephens, this is just the beginning.
Relying on funding and FDA approval, he
eventually will use regenerative medicine
to create vascular bypass vessels and tissueengineered venous valves. To that end, he is
developing a bioreactor with collaborators at
the University of Houston, which will provide
chemical and biomechanical signals to the cells,
mimicking a natural environment. Testing of
cell regeneration in this bioreactor should begin
in May 2012.

Why this matters:

Last year in America, more than 112,000
people waited for organ transplants. Work in
regenerative medicine will allow for treatment
of diseases that are currently untreated due to
organ/tissue shortages. It also will promote new
treatments for diseases, such as diabetes and
heart disease. By learning how tissue grows,
disease processes can be better understood,
leading to more targeted treatments for patients.
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In Brief
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Using Forensic Science to
Solve Dentistry Mysteries

Comparing x-ray images and forensic anthropological skeletal specimens helps link dental pathology to systemic diseases. Shown
here are x-ray and skeletal evidence of a failed root canal resulting in infection in the body.

Dentists have long been able to see how diseases
of the teeth and gums affect the body, but now,
our research is revealing that systemic disease can
first be spotted in the mouth.
The department of General Dentistry’s Gary
McCown, D.D.S., assistant professor, O. Lee
Wilson, D.M.D., associate professor, and Murray
Marks, Ph.D., associate professor, are applying
dental science to forensic anthropological skeletal

specimens from the Regional Forensic Center
and University of Tennessee’s Body Farm. The
team is comparing long-term dental and alveolar
(tooth socket) bone diseases with radiographic
appearance and medical records. This study may
lead to further evidence linking dental pathology
to other systemic diseases like diabetes, heart
disease, stroke and cancer.

Why this matters:

Dentists at the UT Graduate School of Medicine
are learning that the first signs of systemic
disease may be witnessed in the gums, teeth and
underlying bone tissue. With this knowledge,
dental patients can be referred to medical
specialists who may diagnose systemic disease
sooner or prevent it altogether.
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In Brief
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Medical Students Learn
Passion for Research

Students and researchers work collaboratively in the Collmann Medical Student Education Endowment. The 2011 participants
include (Front) Michael Karlstad, Ph.D.; Roger Carroll, Ph.D.; Wissam Tobea; Vincent Irish; (Back) Caroline Conley; Jerrin
Nabers; Valerie Berthelier, Ph.D.; and Deidra Mountain, Ph.D. Not pictured is Robert Craft, M.D.

Empowering medical students with a passion
for research and an understanding of how
research affects patient care was the hope of
I. Reid Collmann, M.D., former dean of the UT
Graduate School of Medicine. To help bring that
hope to reality, the Collmann Medical Student
Education Endowment gives young future
doctors time in research labs, working alongside
experienced researchers.
First- and second-year medical students and
pre-medicine students in undergraduate school
can apply for the eight-week summer program at
the Graduate School of Medicine. Last summer,
four students participated, studying in a variety
of specialities.

Students chosen for the 2011 program and
their respective research topics include
Caroline Conley: Human Nutrition
Vincent Irish: Medicine and Vascular Disease
Jerrin Olivia Nabers: Nutrition and Anesthesiology
Wissam Tobea: Conformational Diseases
Graduate School of Medicine faculty who
mentored the students include
Valerie Berthelier, Ph.D.
Roger Carroll, Ph.D.
Robert Craft, M.D.
Michael Karlstad, Ph.D.
Deidra Mountain, Ph.D.
For information on the Collmann
Endowment, contact Missy Maples, Student
Affairs coordinator, at 865-305-9618.

Why this matters:

Creating passion for research and patient care is
an integral part of educating well prepared and
compassionate physicians.
12

Executive Dean Comments
on Future of Research

News»

Professionals at the UT
Graduate School of Medicine
received clear direction from
David M. Stern, M.D.,
executive dean and interim
vice chancellor for research
at the UT Health Science
David Stern, M.D.,
Center during a recent visit to
Executive Dean
Knoxville: Partnerships.
“The only way to succeed in this economic
and healthcare atmosphere is to partner with the
[University of Tennessee Medical Center] and the
community,” Stern said. “Research endeavors need
to add value to [patient care] now more than ever.”
Stern called for a redefined research mission, one
that supports comparative effectiveness research for
patient-centered outcomes.
The UT Graduate School Medicine will
continue to refine the direction of its programs.
By dovetailing many of the institution’s research
programs with the Centers of Excellence at the
University of Tennessee Medical Center, research
will continue to grow, and the clinical programs at
the centers will be able to provide more cuttingedge patient care.

Research in NICU Technology,
Corneal Defect Receive Funding

Research being conducted by Christopher P.
Stephens, Ph.D., research assistant professor, and
others has received recognition and funding from
the Morris Animal Foundation. The research
investigates new methods using adult donated stem
cells and scaffolding to repair corneal ulceration in
horses, the most common eye problem in humans,
horses, dogs and cats.
Stephens, Vichien Lorch, M.D., and Mark
Gaylord, M.D., also received funding from
the University of Tennessee for technology
development to aid premature infants in neonatal

intensive care. The work is in collaboration with
the Department of Mechanical Engineering at the
University of Houston.
This research includes the development of four
new technologies:
Soft Hydrated Coating for Cannula: The
coating is developed from cellulose in Stephens’s
laboratory and should improve the seal in infants’
nostrils.
Computer-diagnostic Stethoscope: The novel
computer-interfaced stethoscope will detect heart
and lung sounds of premature infants. Using
digital recorders on the stethoscopes, the team will
be able to use the heart and lung sounds to create
diagnostic software.
Apnea Stimulation Device: A new device will
interface with infants’ apnea monitors to gently
stimulate infants when Apnea of Prematurity
is detected.
Breathing-assist Chest Plate: Using a soft
polymer to form a seal against the infant’s skin and
create a slight vacuum, the chest plate will facilitate
respiration. The chest-plate technology could
eliminate the use of endotracheal tubes.

Burn Research Funded

Christy Lawson, M.D.,
instructor in the Department
of Surgery, received the
Norman Yoshimura Grant
from the American Society
of Parenteral and Enteral
Nutrition Rhoads Research
Foundation for her work
on the connection between
angiotensin and insulin in
Christy Lawson, M.D.
burn trauma.
Often in burn trauma, insulin resistance is
increased. The study investigates the crosstalk
between angiotensin—a hormone that raises blood
pressure—and insulin to regulate glucose levels and
aid in treatment of victims of burns.

Your Chance to Advance
The people at the UT Graduate School of Medicine would be happy to discuss
our research programs and how your support can help advance healthcare. For
information about philanthropic giving to the UT Graduate School of Medicine
Office of Research, please contact the development office at 865-305-6611 or
development@utmck.edu.
If you would like more information about any of the research programs described in
this issue of Advance, please contact the UT Graduate School of Medicine at 865-3059290 or visit us online: http://gsm.utmck.edu/research/main.cfm.
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